RESUMEN
Objective: Anticancer drugs have revolutionized tumor therapy, with cutaneous toxicities such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) being common immune-related adverse events. The debate over the efficacy of systemic corticosteroids in treating these conditions persists, while tumor necrosis factor (TNF)-alpha inhibitors show promise. This study aims to evaluate the effectiveness and safety of combination therapy involving the TNF-α inhibitor adalimumab for SJS/TEN induced by anticancer drugs. Methods: A literature review of SJS/TEN cases induced by anticancer drugs from 1992 to 2023 was conducted, alongside an analysis of patients admitted to the First Affiliated Hospital of Fujian Medical University during the same period. Clinical characteristics, skin healing time, mortality, and adverse events were evaluated in two treatment groups: SJS/TEN patients treated with targeted anticancer therapies and immunotherapies. Results: Among the 27 patients studied (18 with SJS or SJS-TEN overlapping and 9 with TEN), combination therapy with adalimumab significantly reduced mucocutaneous reepithelization time and healing duration compared to corticosteroid monotherapy. Patients receiving adalimumab combined with corticosteroids had lower actual mortality rates than those on corticosteroid monotherapy. The combination therapy also showed a trend towards reducing standardized mortality rates based on the Score of Toxic Epidermal Necrolysis (SCORTEN). Conclusion: The findings suggest that adalimumab in combination with corticosteroids provides significant clinical benefits and is safer than corticosteroids alone for treating SJS/TEN induced by targeted anticancer therapies and immunotherapies. This study contributes valuable insights into potential treatment strategies for severe cutaneous adverse reactions to anticancer drugs, highlighting the importance of exploring alternative therapies such as TNF-α inhibitors in managing these conditions effectively.
RESUMEN
Two biobased composite films have been prepared with poly (lactic acid-trimethylene carbonate), polylactic acid and Laponite by solvent evaporation method. The 1H NMR and FTIR spectrums illustrate that P (LA-TMC) polymer is successfully synthesized and designed composite films are produced. Morphometric analyses demonstrate that the roughnesses of the film's surface and cross-section are on the increase with higher PLA and Laponite content. Mechanical performances reveal that the rise in tensile strength and modulus while maintaining excellent elongation at break is mainly due to the increase in the content of polylactic acid and Laponite. By utilizing the nano effect of Laponite, the maximum tensile strength of the composite film reaches 34.59 MPa. Thermal property results illustrate that the Tg and initial decomposition temperature are on the growth with the increase of PLA content. However, it is not significant on the effect of Laponite on the initial decomposition temperature. The water vapor permeability measurements prove that the barrier property of P(LA-TMC)/PLA/Laponite composite film is on the ascent with the Laponite addition. Hydrolytic degradation tests indicate that PLA and Laponite play avital part in accelerating the degradation rate of composite films and alkaline media is superior acidic and neutral conditions.
Asunto(s)
Dioxanos , Ácido Láctico , Polímeros , Silicatos , Ácido Láctico/química , Polímeros/química , Poliésteres/químicaRESUMEN
The extraction process of Paeoniae radix alba polysaccharides (PRAP) was optimized as the liquid-solid ratio of 10.65 mL/g, the extraction time of 2.10 h, and the 2 extraction repetitions through a response surface methodology. The chemical profiles of the obtained PRAP were characterized by measuring the contents of total carbohydrates, total phenolics, uronic acid and protein, and by analyzing the FT-IR spectrum and monosaccharide composition. To determine the therapeutic effects of PRAP on experimental autoimmune hepatitis (EAH), we established an EAH mice model. After treated with PRAP, liver and spleen injuries were reduced, and hepatocyte regeneration and liver function were improved. Further study of the mechanism by which PRAP treats EAH showed that PRAP significantly inhibited oxidative stress in the livers of EAH model mice. More importantly, PRAP inhibited immune inflammatory reactions in EAH model mice, including the hepatic infiltration of inflammatory CD4+ and CD8+ T cells, as well as overexpression of inflammatory cytokines IL-2, IL-6 and IL-10, via inhibition of the NF-κB signaling pathway.
Asunto(s)
Hepatitis Autoinmune/tratamiento farmacológico , Paeonia/química , Polisacáridos/farmacología , Animales , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/metabolismo , Carbohidratos/farmacología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/farmacología , Hepatitis Autoinmune/metabolismo , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Estrés Oxidativo/efectos de los fármacos , Fenoles/farmacología , Transducción de Señal/efectos de los fármacos , Bazo/efectos de los fármacos , Bazo/metabolismo , Ácidos Urónicos/farmacologíaRESUMEN
IgG molecules exert important effector functions including complement-dependent cytotoxicity (CDC). Different IgG isotypes induce CDC effect with variation, largely due to their differential binding to C1q, the initiating molecule of the classical CDC pathway. Here we report a method to characterize the binding of IgG to C1q using label-free technique. With this method, we determined the binding affinities of multiple IgG1, IgG2 and IgG4 antibodies to C1q. To explore whether antigen binding to antibodies affects C1q binding, we assessed the binding of Trastuzumab and Adalimumab with bound antigen proteins to C1q. The results showed that although the two tested IgG1 mAbs alone bind C1q similarly, their FC binding to C1q was significantly impacted by antigen binding to the Fab. The data suggested that the first step of complement pathway, whether C1q binds target cell bound antibody molecules, may significantly affect the CDC activities of antibody drugs.
Asunto(s)
Adalimumab/inmunología , Reacciones Antígeno-Anticuerpo , Complemento C1q/inmunología , Inmunoglobulina G/inmunología , Trastuzumab/inmunología , Humanos , Interferometría/métodosRESUMEN
Food contamination by toxic mycotoxins not only causes a considerable loss in economy, but importantly poses a huge threat to human health through accidental ingestion. Hence, it is an ongoing and imperative need to develop a convenient, cost-effective method for the detection of the mycotoxin-infected agricultural commodities. To this end, we herein fabricated a novel metal-organic framework-derived composite material that displays a strong solid-state emission in the visible region, by attaching a frequently used fluorescent label, fluorescein isothiocyanate (FITC), via guest adsorption. Significantly, owing to the inherent pH-responsive conformational changes of FITC, the resulting composite material provides, to the best of our knowledge, the first example of the sensitive and selective fluorescence sensing toward 3-nitropropionic acid, which, as a major naturally occurring mycotoxin in moldy sugarcane, has been closely linked to poisoning episodes in human beings and animals.
Asunto(s)
Estructuras Metalorgánicas/química , Animales , Fluorescencia , Luminiscencia , Micotoxinas , Porosidad , SaccharumRESUMEN
By means of a mixed-ligand strategy, a novel bi-functional metal-organic framework, [H2N(CH3)2]·Zn(NDC)(atz)·H2O (NDC = 2,6-naphthalenedicarboxylic acid, Hatz = 1H-tetrazol-5-amine), was synthesized, which displays a three-dimensional two-fold interpenetrated framework. Owing to the introduction of two different functional organic ligands, this complex exhibits bi-functional properties, i.e., selective gas adsorption of CO2 over CH4 and fluorescence sensing response for nitrobenzene.
RESUMEN
It has been well documented that the Toll-like receptor 4 (TLR4)/NF-κB signaling pathway mediates early inflammatory responses during myocardial ischemia and reperfusion (MI/R). Mycophenolate mofetil (MMF), an immunosuppressive agent, has been shown to confer protective effects against ischemia/reperfusion injury, possibly through its immunosuppressive and anti-inflammatory actions. The aim of the present study was to investigate whether MMF could modulate the TLR4/NF-κB signaling, inhibit cell apoptosis and subsequently attenuate MI/R injury. MMF (20 mg/kg) or vehicle was administered to SD rats by gavage. The rats were then subjected to MI/R injury. The results showed that after MI/R, the expressions of myocardial TLR4 and NF-κB were significantly increased, and apoptosis of cardiomyocytes was induced, as evidenced by the decreased mitochondrial membrane potential (MMP), decreased Bcl-2 protein level, and increased Bax expression. Administration of MMF attenuated MI/R injury. Further studies demonstrated that MMF inhibited the induction of TLR4, NF-κB and Bax expression, and restored the expression of bcl-2. Moreover, increased myeloperoxidase activity and serum level of tumor necrotic factor α induced by MI/R injury were also inhibited by MMF treatment. In conclusion, our results demonstrated that MMF attenuates MI/R injury through inhibition of the TLR4/NF-κB signaling pathway, which led to reduced inflammatory reaction and subsequently myocardial cell apoptosis.
Asunto(s)
Inmunosupresores/uso terapéutico , Ácido Micofenólico/análogos & derivados , Daño por Reperfusión Miocárdica/tratamiento farmacológico , FN-kappa B/efectos de los fármacos , Receptor Toll-Like 4/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Corazón/efectos de los fármacos , Masculino , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ácido Micofenólico/uso terapéutico , Miocitos Cardíacos/efectos de los fármacos , Neutrófilos/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Proteína X Asociada a bcl-2/biosíntesisRESUMEN
The aim of this work was to prepare tetracycline-loaded solid lipid nanoparticles (Tet-SLN), and to evaluate the potential of these colloidal carriers for subcutaneous injection. Tet-SLN was prepared by microemulsion method and the preparation conditions were optimized by ternary phase diagram. At optimized process conditions, lyophilized Tet-SLN showed spherical particles with a mean diameter of 87.2±46.9 nm and a negative zeta potential of -6.69 mV, up to 1.7% tetracycline drug content was achieved after loading. In vitro release test showed a biphasic release profile for Tet-SLN and more than 80% of the drug was liberated from Tet-SLN in 48 h. After subcutaneous injection of Tet-SLN to mice, a considerable sustained release was observed; tetracycline in blood could be detected lasting 36 h, and lower concentrations of tetracycline in all tissues tested compared to the free tetracycline solution were observed. In conclusion, Tet-SLN can be prepared well by microemulsion method and subcutaneous injection of SLN provide a new perspective for drug sustained release.